BCHE and early-onset autosomal dominant Alzheimer disease: This binding of MQ to BuChE (−9.755 kCal/mol) was comparable in affinity to that calculated for the commercial phytochemical drug, galantamine (−10.587 kCal/mol) (results not included), used as a first-line cholinesterase inhibitor treatment for Alzheimer’s disease.